Pancreatic Cancer Research

ResearcherSt. Michael's HospitalNo recent work listed

Ming‐Sound Tsao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9160-5405; OpenAlex author ID A5073362806. Sources: OpenAlex.

Their work

Papers
13 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper

Papers 13

  1. Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41388-019-0985-1↗
  2. Targeting NAD(P)H:Quinone Oxidoreductase (NQO1) in Pancreatic Cancer. Co-author DOI 10.1002/mc.20199↗
  3. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Co-author DOI 10.1038/nature19823↗
  4. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Co-author DOI 10.1038/bjc.2015.220↗
  5. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Co-author DOI 10.1038/nm.3973↗
  6. Coiled-coil domain containing 68 (CCDC68) demonstrates a tumor-suppressive role in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/onc.2014.357↗
  7. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2014.04.008↗
  8. SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/β-catenin signaling. Last author DOI 10.1038/onc.2012.595↗
  9. Regulation of pancreatic cancer growth by superoxide. Co-author DOI 10.1002/mc.21891↗
  10. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  11. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-11-1079↗
  12. Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma. Last author DOI 10.1371/journal.pone.0046677↗
  13. Role of Rac1-dependent NADPH oxidase in the growth of pancreatic cancer. Co-author DOI 10.1038/cgt.2010.64↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nikolina Radulovich · 4 shared papers, 2012–2020 · strength 0.25
  2. Tao Wang · 2 shared papers, 2016–2020 · strength 0.17
  3. Joseph J. Cullen · 3 shared papers, 2011–2017 · strength 0.15
  4. Joella Joseph · 1 shared paper, 2020 · strength 0.13
  5. Steve Gallinger · 3 shared papers, 2015–2016 · strength 0.12
  6. Juan Du · 2 shared papers, 2013–2017 · strength 0.12
  7. Kelsie L. Thu · 2 shared papers, 2014–2015 · strength 0.09
  8. Anne Marie Lewis · 1 shared paper, 2017 · strength 0.08
  9. David William Hedley · 2 shared papers, 2014–2015 · strength 0.08
  10. Ines Lohse · 2 shared papers, 2015 · strength 0.08
  11. Ayelet Borgida · 2 shared papers, 2015–2016 · strength 0.08
  12. Daniel John Renouf · 2 shared papers, 2014–2015 · strength 0.08
  13. Lisa Leung · 2 shared papers, 2012–2015 · strength 0.07
  14. Sean Patrick Cleary · 2 shared papers, 2015–2016 · strength 0.07
  15. Ashton Anthony Connor · 2 shared papers, 2015–2016 · strength 0.07
  16. Michael H. A. Roehrl · 2 shared papers, 2015–2016 · strength 0.07
  17. Eric R. Siegel · 1 shared paper, 2012 · strength 0.04
  18. Vladimir V. Iakovlev · 1 shared paper, 2012 · strength 0.04
  19. Randy S. Haun · 1 shared paper, 2012 · strength 0.04
  20. Jason Moffat · 1 shared paper, 2015 · strength 0.04
  21. Neesha C. Dhani · 1 shared paper, 2014 · strength 0.04
  22. Sharlene Gill · 1 shared paper, 2014 · strength 0.04
  23. Malcolm J. Moore · 1 shared paper, 2014 · strength 0.04
  24. Ling Huang · 1 shared paper, 2015 · strength 0.04
  25. Steve E. Kalloger · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.